Abstract:Background: Perinatal mood and anxiety disorders encompass a range of mental health disorders that occur during pregnancy and up to 1 year postpartum, affecting approximately 20% of women. Traditional risk factors, such as a history of depression and pregnancy complications including preeclampsia, are known. Their predictive utility, however, is not specific or sensitive enough to inform clinical decision-making or prevention strategies for perinatal mood and anxiety disorders. Better diagnostic and prognostic models are needed for early identification and referral to treatment. Objective: This study aimed to determine if a panel of novel third-trimester plasma protein biomarkers in pregnant women can be used to identify those who have a high predisposed risk for perinatal mood and anxiety disorders within 3 months postpartum. Study design: We studied 52 women (n=34 with a risk for perinatal mood and anxiety disorders and n=18 controls) among whom mental health screening was conducted at 2 time points, namely in the third trimester and again at 3 months postdelivery. An elevated perinatal mood and anxiety disorder risk was identified by screening individuals with above-validated cutoffs for depression (Edinburgh Postnatal Depression Scale ≥12), anxiety (Overall Anxiety Severity and Impairment Scale ≥7), and/or posttraumatic stress disorder (Impact of Events Scale >26) at both time points. Plasma samples collected in the third trimester were screened using the aptamer-based SomaLogic SomaScan proteomic assay technology to evaluate perinatal mood and anxiety disorder-associated changes in the expression of 1305 protein analytes. Ingenuity Pathway Analysis was conducted to highlight pathophysiological relationships between perinatal mood and anxiety disorder-specific proteins found to be significantly up- or down-regulated in all subjects with perinatal mood and anxiety disorder and in those with perinatal mood and anxiety disorders and no preeclampsia. Results: From a panel of 53 significant perinatal mood and anxiety disorder-associated proteins, a unique 20-protein signature differentiated perinatal mood and anxiety disorder cases from controls in a principal component analysis (P<.05). This protein signature included NCAM1, NRCAM, and NTRK3 that converge around neuronal signaling pathways regulating axonal guidance, astrocyte differentiation, and maintenance of GABAergic neurons. Interestingly, when we restricted the analysis to subjects without preeclampsia, a 30-protein signature differentiated perinatal mood and anxiety disorder cases from all controls without overlap on the principal component analysis (P<.001). In the nonpreeclamptic perinatal mood and anxiety disorder group, we observed increased expression of proteins, such as CXCL11, CXCL6, MIC-B, and B2MG, which regulate leucocyte migration, inflammation, and immune function. Conclusion: Participants with perinatal mood and anxiety disorders had a unique and distinct plasma protein signature that regulated a variety of neuronal signaling and proinflammatory pathways. Additional validation studies with larger sample sizes are needed to determine whether some of these molecules can be used in conjunction with traditional risk factors for the early detection of perinatal mood and anxiety disorders.

Effects of Pregnancy and Delivery on the Availability of Plasma Tryptophan to the Brain: Relationships to Delivery-Induced Immune Activation and Early Post-Partum Anxiety and Depression.

Depressive and Anxiety Symptoms in the Early Puerperium Are Related to Increased Degradation of Tryptophan into Kynurenine, a Phenomenon Which is Related to Immune Activation

Disturbances in dexamethasone suppression test and lower availability of Ł-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy

Disturbances in dexamethasone suppression test and lower availability of L-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy

IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome

Effects of Pregnancy and Delivery on Serum Concentrations of Clara Cell Protein (CC16), an Endogenous Anticytokine: Lower Serum CC16 is Related to Postpartum Depression

Immune Activation in the Early Puerperium is Related to Postpartum Anxiety and Depressive Symptoms

Relationships Between Lower Plasma L-tryptophan Levels and Immune-Inflammatory Variables in Depression

Cytokines and tryptophan metabolites can predict depressive symptoms in pregnancy

Body Image Dissatisfaction in Pregnant and Non-Pregnant Females is Strongly Predicted by Immune Activation and Mucosa-Derived Activation of the Tryptophan Catabolite (TRYCAT) Pathway

IgA/IgM Responses to Gram-Negative Bacteria Are Not Associated with Perinatal Depression, but with Physio-Somatic Symptoms and Activation of the Tryptophan Catabolite Pathway at the End of Term and Postnatal Anxiety.

Pathological shifts in tryptophan metabolism in human term placenta exposed to LPS or poly I:C†

Differential Distribution of Tryptophan-Metabolites in Fetal and Maternal Circulations During Normotensive and Preeclamptic Pregnancies

Dynamics of Tryptophan Metabolic Pathways in Human Placenta and Placental-Derived Cells: Effect of Gestation Age and Trophoblast Differentiation

The Inflammatory Response System and the Availability of Plasma Tryptophan in Patients with Primary Sleep Disorders and Major Depression.

The Effect of Trophoblasts on T Lymphocytes: Possible Regulatory Effector Molecules - A Proteomic Analysis

In the Puerperium, Primiparae Exhibit Higher Levels of Anxiety and Serum Peptidase Activity and Greater Immune Responses Than Multiparae.

First-trimester maternal tryptophan metabolites, utero-placental (vascular)development and hypertensive disorders of pregnancy: The Rotterdam periconceptional cohort

Human placental lactogen (human chorionic somatomammotropin) and oxytocin during pregnancy: Individual patterns and associations with maternal-fetal attachment, anxiety, and depression

Serotonin-immune Interactions in Major Depression: Lower Serum Tryptophan As a Marker of an Immune-Inflammatory Response

Perinatal mood and anxiety disorders: biomarker discovery using plasma proteomics